Casdin Capital, LLC - Q4 2022 holdings

$1.29 Billion is the total value of Casdin Capital, LLC's 46 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 40.5% .

 Value Shares↓ Weighting
SRPT BuySAREPTA THERAPEUTICS INC$170,397,700
+25.8%
1,315,000
+7.3%
13.20%
+48.4%
BLFS  BIOLIFE SOLUTIONS INC$137,735,266
-20.0%
7,566,2920.0%10.67%
-5.6%
 EQRX INC$97,238,066
-50.3%
39,527,6690.0%7.53%
-41.4%
ALNY SellALNYLAM PHARMACEUTICALS INC$86,742,250
-33.1%
365,000
-43.7%
6.72%
-21.1%
ILMN  ILLUMINA INC$77,847,000
+6.0%
385,0000.0%6.03%
+25.0%
BPMC SellBLUEPRINT MEDICINES CORP$64,742,418
-42.2%
1,477,800
-13.1%
5.02%
-31.8%
RVMD BuyREVOLUTION MEDICINES INC$60,145,500
+20.9%
2,525,000
+0.1%
4.66%
+42.6%
SellMAXCYTE INC$51,897,300
-25.6%
9,505,000
-11.5%
4.02%
-12.3%
RLAY SellRELAY THERAPEUTICS INC$45,277,881
-56.8%
3,030,648
-35.3%
3.51%
-49.0%
VERV SellVERVE THERAPEUTICS INC$44,322,549
-59.4%
2,290,571
-27.9%
3.43%
-52.1%
DNLI BuyDENALI THERAPEUTICS INC$36,153,000
+18.4%
1,300,000
+30.7%
2.80%
+39.6%
PLRX BuyPLIANT THERAPEUTICS INC$32,377,750
+106.6%
1,675,000
+123.3%
2.51%
+143.8%
 SOMALOGIC INC$31,636,730
-13.4%
12,604,2750.0%2.45%
+2.1%
EXAS SellEXACT SCIENCES CORP$27,973,150
-11.0%
565,000
-41.6%
2.17%
+5.0%
ABCL BuyABCELLERA BIOLOGICS INC$22,995,100
+40.9%
2,270,000
+37.6%
1.78%
+66.2%
TWST BuyTWIST BIOSCIENCE CORP$22,500,450
+74.9%
945,000
+158.9%
1.74%
+106.3%
MRTX BuyMIRATI THERAPEUTICS INC$21,522,250
+23.3%
475,000
+90.0%
1.67%
+45.4%
FATE  FATE THERAPEUTICS INC$20,684,500
-55.0%
2,050,0000.0%1.60%
-46.9%
RNA NewAVIDITY BIOSCIENCES INC$18,861,500850,000
+100.0%
1.46%
Buy2SEVENTY BIO INC$17,334,500
+93.8%
1,850,000
+200.9%
1.34%
+128.4%
NVTA BuyINVITAE CORP$16,811,402
+506.9%
9,038,388
+702.8%
1.30%
+615.9%
RXDX NewPROMETHEUS BIOSCIENCES INC$16,500,000150,000
+100.0%
1.28%
IPSC  CENTURY THERAPEUTICS INC$16,448,729
-48.1%
3,206,3800.0%1.27%
-38.8%
SellABSCI CORPORATION$15,462,846
-36.0%
7,363,260
-4.6%
1.20%
-24.5%
BEAM  BEAM THERAPEUTICS INC$14,470,700
-17.9%
370,0000.0%1.12%
-3.2%
FDMT New4D MOLECULAR THERAPEUTICS IN$13,992,300630,000
+100.0%
1.08%
NewPRIME MEDICINE INC$13,644,223734,350
+100.0%
1.06%
BuyTENAYA THERAPEUTICS INC$12,218,509
+17.5%
6,078,860
+69.5%
0.95%
+38.7%
MRNA BuyMODERNA INC$10,777,200
+180.4%
60,000
+84.6%
0.84%
+231.3%
NTLA  INTELLIA THERAPEUTICS INC$10,292,550
-37.7%
295,0000.0%0.80%
-26.5%
VEEV NewVEEVA SYS INC$8,069,00050,000
+100.0%
0.62%
ARVN  ARVINAS INC$6,842,000
-23.1%
200,0000.0%0.53%
-9.2%
INCY NewINCYTE CORP$6,224,80077,500
+100.0%
0.48%
MRNA NewMODERNA INCcall$5,388,60030,000
+100.0%
0.42%
NewDICE THERAPEUTICS INC$5,148,000165,000
+100.0%
0.40%
MRTX  MIRATI THERAPEUTICS INCcall$4,531,000
-35.1%
100,0000.0%0.35%
-23.5%
OPRX NewOPTIMIZERX CORP$4,368,000260,000
+100.0%
0.34%
 SEMA4 HOLDINGS CORP$4,336,213
-69.9%
16,437,5000.0%0.34%
-64.5%
NewDEFINITIVE HEALTHCARE CORP$3,956,400360,000
+100.0%
0.31%
GLUE  MONTE ROSA THERAPEUTICS INC$3,887,812
-6.9%
510,8820.0%0.30%
+9.9%
KROS NewKEROS THERAPEUTICS INC$3,121,30065,000
+100.0%
0.24%
OMIC  SINGULAR GENOMICS SYSTEMS IN$2,704,901
-19.6%
1,345,7220.0%0.21%
-5.0%
WVE NewWAVE LIFE SCIENCES LTD$1,400,000200,000
+100.0%
0.11%
 EXSCIENTIA PLCads$1,140,087
-35.1%
213,9000.0%0.09%
-23.5%
 LIANBIOsponsored ads$338,521
-17.6%
206,4150.0%0.03%
-3.7%
KRON  KRONOS BIO INC$200,619
-51.7%
123,8390.0%0.02%
-40.7%
MGTA ExitMAGENTA THERAPEUTICS INC$0-320,000
-100.0%
-0.03%
CERE ExitCEREVEL THERAPEUTICS HLDNG I$0-80,000
-100.0%
-0.15%
CLDX ExitCELLDEX THERAPEUTICS INC NEW$0-165,000
-100.0%
-0.30%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BLUEPRINT MEDICINES CORP32Q3 20239.6%
ALNYLAM PHARMACEUTICALS INC32Q3 20239.9%
AGIOS PHARMACEUTICALS INC27Q2 202212.1%
GLOBAL BLOOD THERAPEUTICS IN27Q2 20227.1%
FATE THERAPEUTICS INC26Q3 20238.3%
BIOLIFE SOLUTIONS INC22Q3 202314.9%
CODEXIS INC22Q3 20238.1%
SAREPTA THERAPEUTICS INC21Q3 202313.6%
BLUEBIRD BIO INC21Q4 20207.8%
ILLUMINA INC21Q3 20236.0%

View Casdin Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Casdin Capital, LLC Q4 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Absci CorpMay 08, 20234,448,2604.8%
CODEXIS, INC.Sold outFebruary 14, 202300.0%
DermTech, Inc.Sold outFebruary 14, 202300.0%
Invitae CorpFebruary 14, 20239,038,3883.7%
Magenta Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Tango Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Verve Therapeutics, Inc.February 14, 20232,290,5713.7%
Tenaya Therapeutics, Inc.December 07, 20226,427,2009.9%
Fulcrum Therapeutics, Inc.February 11, 20211,241,1764.5%
Gritstone Oncology, Inc.Sold outFebruary 11, 202100.0%

View Casdin Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-08
42024-03-28
32024-03-25
42024-03-25
42024-03-20
SC 13D/A2024-03-20
42024-03-06
42024-03-06
13F-HR2024-02-14
SC 13G/A2024-02-14

View Casdin Capital, LLC's complete filings history.

Compare quarters

Export Casdin Capital, LLC's holdings